EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men

Christian Friedrich iD, Dave Singh iD, Klaus Francke, Stefan Klein, Terence Hetzel, Oliver Zolk, Isabella Gashaw, Christian Scheerans, Alyn Morice

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16091 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Christian Friedrich und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bayer AG, Berlin, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A, Purinergic P2X Receptor Antagonists, Drug Interactions, Midazolam. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We report on investigations exploring the P2X3‐receptor antagonist filapixant's effect on taste perception and cough‐reflex sensitivity and describe its pharmacokinetics, including its CYP3A4‐interaction potential.

Methods

In a randomized, placebo‐controlled, double‐blind study, 3 × 12 healthy men (18‐45 years) were assigned (3:1) to filapixant (20, 80 or 250 mg by mouth) or placebo twice daily over 2 weeks. A single dose of midazolam (1 mg), a CYP3A4 substrate, was administered with and without filapixant. Assessments included a taste‐strips test, a taste questionnaire, cough challenge with adenosine triphosphate, adverse event reports and standard safety assessments.

Results

Taste disturbances were observed mainly in the 250‐mg group: six of nine participants (67%) in this group reported hypo‐ or dysgeusia in the questionnaire; eight participants (89%) reported taste‐related adverse events. Five participants (56%) had a decrease in overall taste‐strips‐test scores ≥2 points (point estimate −1.1 points, 90% confidence interval [−3.3; 1.1]). Cough counts increased with adenosine triphosphate concentration but without major differences between treatments. Filapixant exposure increased proportionally to dose. Co‐administration of filapixant had no clinically relevant effect on midazolam pharmacokinetics. Area under the concentration‐time curve ratios and 90% confidence intervals were within 80‐125%. No serious or severe adverse events were reported.

Conclusions

Overall, filapixant was safe and well tolerated, apart from mild, transient taste disturbances. Such disturbances occurred more frequently than expected based on (in vitro) receptor‐selectivity data, suggesting that other factors than P2X3:P2X2/3 selectivity might also play an important role in this context. The cough‐challenge test showed no clear treatment effect. Filapixant has no clinically relevant CYP3A4 interaction potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP3APurinergic P2X Receptor AntagonistsDrug InteractionsMidazolamDose-Response Relationship, DrugHumansMaleAdultDouble-Blind MethodYoung AdultAdolescentHealthy VolunteersMiddle AgedCoughTasteReceptors, Purinergic P2X3

Stichwörter der Autor:innen

assessment of taste functioncough‐reflex sensitivitypurinergic receptorsreceptor pharmacologyrefractory chronic coughtaste disturbancestaste strips

Substanzen

Cytochrome P-450 CYP3APurinergic P2X Receptor AntagonistsMidazolamCYP3A4 protein, humanReceptors, Purinergic P2X3

Autor:innen und Institutionen

  • Bayer AG, Berlin, Germany.
  • Brandenburg Medical School Theodor Fontane, Faculty of Health Sciences Brandenburg, Brandenburg an der Havel, Germany.
  • Medicines Evaluation Unit, Division of Infection, Immunity & Respiratory Medicine, Manchester University NHS Foundations Trust & University of Manchester, Manchester, UK.
  • Brandenburg Medical School Theodor Fontane, Faculty of Health Sciences Brandenburg, Rüdersdorf, Germany.
  • Hull York Medical School, University of Hull, Hull, UK.

ORCID-Profile: Christian Friedrich, Dave Singh

Zitieren

APA

Friedrich, C., Singh, D., Francke, K., Klein, S., Hetzel, T., Zolk, O., Gashaw, I., Scheerans, C., & Morice, A. (2024). Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16091

Vancouver

Friedrich C, Singh D, Francke K, Klein S, Hetzel T, Zolk O, et al. Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16091

BibTeX
@article{Friedrich2024,
  author = {Friedrich, Christian and Singh, Dave and Francke, Klaus and Klein, Stefan and Hetzel, Terence and Zolk, Oliver and Gashaw, Isabella and Scheerans, Christian and Morice, Alyn},
  title = {Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16091}
}
Kostenlos starten →